Results from an international phase 3 trial of Johnson & Johnson's single-dose COVID-19 vaccine show it is overall 66% effective in preventing moderate to severe symptoms of COVID-19.
The vaccine was 85% effective in preventing COVID-19-related hospitalizations and deaths.The vaccine has been a long-hoped for game-changer in the global fight against the pandemic because it requires only one dose, can be manufactured in billions of doses, and requires only standard refrigeration."A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance.